Bausch + Lomb eyes 2027 trial start for oral dry AMD drug
Tweet Send to a Friend
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




